“The development potential of Asia is very appealing for the Russian pharmaceutical business and the industry’s unions are the best for which to implement potential cooperation between pharmaceutical companies,” spoke ARPM Director General, Victor Dmitriev at the International Forum “Russia- Asia”.

    Cooperation with our Asian partners traditionally has been one of the main direction of the work of the Association. We made several contracts on collaboration with industry’s unions of China, Japan, and South Korea. “Each of these countries has a great potential in particular directions of pharma. Thus China is the main supplier of pharmaceutical substances, companies from Japan are actively allocating their production in Russia, and South Korea helps to transfer technologies. However, the Asian market is not only interesting to us as a supplier, but also as a sales market. Russian pharmaceutical companies are present in the Southeast Asian market: Vietnam, Malaysia, and negotiations are underway with Indonesia,” Mr. Dmitriev. Among the primary directions of cooperation Mr. Dmitriev noted educational programs, improvement of regulatory systems and fight against counterfeiting medicines. “We plan to further work with our partners in Asia for design and production of effective, export-oriented and affordable medicine.”

Mr. Dmitirev also noted that the pharmaceutical industry in Russia is one of the most socially important in the Russian economy and is very regulated. However, the strict regulation does not turn away investors. Even in crisis foreign companies invest in Russia and provide a study growth for the economy.

The Forum showed that Asian is open for cooperation with Russian entrepreneurs. A lot of countries in the region provide preferences and tax exemptions to ease the entrance on their markets.